Columbia University Medical Center scientists have developed a new “personalized immune mouse,” a new tool that allows them to re-create an individual’s immune system to study autoimmune diseases.
U.S. Army Col. George Peoples, chief of surgical oncology at the San Antonio Military Medical Center, says he has come up with a vaccine he thinks will prevent cancer.
A randomized, double-blind study was conducted to demonstrate the immunologic noninferiority of an investigational quadrivalent live attenuated influenza vaccine (Q/LAIV) developed by MedImmune.
On March 26 2012, the U.S. Supreme Court instructed the Federal Circuit Court of Appeals to reconsider its July 2011 decision to uphold patents held by Myriad Genetics.
CSL Behring has been granted orphan drug designation by the U.S.Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
A multinational team of investigators exposed cultured neurons with intravenous immunoglobulin (IVIG) to evaluate its effect on downstream signaling pathways involved in neuronal cell death.
Updates about vaccines, including Alzheimer's disease, HPV, brain cancer, colorectal cancer, non-small cell lung cancer, prostate cancer and more.
In May 2012, the Texas Legislature passedSenate Bill 1107, a law that requires new college students to provide proof of receiving a bacterial meningitis vaccine10 days prior to the start of classes.
A genetically engineered smallpox vaccine reduced the risk of death for patients with advanced liver cancer by nearly 60 percent in a mid-stage study.
With the looming deadline to create health insurance exchanges, states are being encouraged to do all they can this year to prepare for their successful launch in 2014.
A recent study showed that recombinant polyclonal antibody drug candidate rozrolimupab exhibited a favorable safety profile and induced a rapid increase in blood platelets inpatients with immune thrombocytopenia purpura.
Recent studies suggest that the divergent outcomes in Alzheimer’s disease clinical studies of intravenous immune globulin (IVIG) may be due to differences in temporal administration and administered dosages.